Moderna announced changes to its operating model to bring focus to its short- and long-term business goals.

The company is focused on driving continued sales of its COVID-19 vaccine and launching its RSV vaccine in 2024, while also preparing to launch multiple products per year from 2025 forward. The company has decided to increase executive focus on driving sales of Spikevax and the expected launch of its RSV vaccine next year.

To do this, Stephane Bancel, Chief Executive Officer of Moderna, will assume responsibility for sales and marketing in 2024, working directly with the commercial team. To ensure the company also maintains momentum on its launches beyond 2024, Stephen Hoge, M.D., President of Moderna, will assume responsibility for pipeline commercial strategy and for Medical Affairs. As part of these changes, Arpa Garay, previously Chief Commercial Officer, is expected to leave the company in the coming months and will remain an advisor during the transition.

"We made significant progress in 2023 and are excited about the year ahead as we focus on driving continued sales in 2024 and 2025," said Stéphane Bancel, Chief Executive Officer of Moderna. "I am grateful for Arpa's leadership and for her help in establishing a strong commercial foundation. Our strategy is clear, our pipeline continues to be highly productive, and we will remain focused on execution."